Tag: Cagrilintide

While both medications target metabolic health, semaglutide is a GLP-1 receptor agonist, whereas cagrilintide is an amylin analogue. Understanding the core difference between semaglutide and cagrilintide is crucial, as this distinction affects their mechanisms of action and overall clinical effects, particularly when used in the combined drug CagriSema.

According to clinical trials, cagrilintide is a long-acting amylin analogue, allowing for a convenient once-weekly injection schedule for weight management. This dosing frequency simplifies the treatment regimen compared to older medications and is made possible by the drug's engineered stability.